Molecular genetic events in adult acute lymphoblastic leukemia

Expert Review of Molecular Diagnostics

Volumn 3, Issue 3, 2003, Pages 339-355

  Gleissner, Beate ^a   Thiel, Eckhard ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute lymphoblastic leukemia; Adults; Diagnostics; Molecular genetics background

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CELL CYCLE; CHIMERA; CHROMOSOME ABERRATION; DISEASE COURSE; ENHANCER REGION; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR CLONING; MOLECULAR GENETICS; ONCOGENE; PROGNOSIS; PROMOTER REGION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; STATISTICAL SIGNIFICANCE; TRANSCRIPTION REGULATION;

ADULT; CHROMOSOME ABERRATIONS; GENE DELETION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MUTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 0037610972     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.3.3.339     Document Type: Review

References (174)

1. Ludwig W-D, Rieder H, Bartram CR et al. Immunophenotypic and genotypic features, clinical characteristics and treatment outcome of adult pro-B acute lymphoblastic leukaemia: results of the German Multicenter Trials GMALL 03/87 and 04/ 89. Blood 92(6), 1898-1909 (1998). Overview of the clinical and genetic features of pro-B precursor acute lymphoblastic leukemia (ALL) patients with MLL gene rearrangements including follow-up data.
2. Gleissner B, Rieder H, Thiel E et al. Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data. Leukemia 15(12), 1834-1840 (2001).
3. Gleissner B, Gökbuget N, Bartram CR et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lienage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99(5), 1356-1543 (2002). Clinical and follow-up data on 432 patients with adult ALL focusing on BCR-ABL- positive patients.
4. Aguiar RC, Sohal J, van Rhee F et al. TEL-AML1 fusion in acute lymphoblastic leukemia of adults. MRC Adult Leukemia Working Party. Br. J. Haematol. 95(4), 673-677 (1996).
5. Jabber Al-Obaidi MS, Martineau M et al. ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukaemia. Leukemia 16(4), 669-674 (2002).
6. Foa R, Vitale A, Mancini M et al. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br. J. Haematol. 120, 484-487 (2003).
7. Bloomfield CD, Goldman AI, Alimena G et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood 67, 415-420 (1986). Overview of the cytogenetic and follow-up data of 329 patients with ALL supporting the requirement for cytogenetic diagnostics.
8. Macintyre EA, Smit L, Ritz J, Kirsch LR, Strominger JL. Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor αβ lineage. Blood 80, 1511-1520 (1992).
9. Janssen JW, Ludwig WD, Sterry W, Bartram CR. SIL-TAL1 deletion in T-cell acute lmyphoblastic leukemia. Leukemia 7(8), 1204-1210 (1993).
10. Grütz GG, Bucher K, Lavenir I, Larson T, Larson R, Rabbitts TH. The oncogenic T-cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T-cells. EMBO J. 17(16), 4594-4605 (1998).
11. Pear WS, Aster JM, Scott ML et al. Exclusive development of T-cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J. Exp. Med 183, 2283-2291 (1996).
12. Hatano M, Roberts CWM, Minden M, Crist WM, Korsmeyer SJ. Deregulation of a homeobox gene, HOX11, by the t(10;14) in T-cell leukemia. Science 253, 79-82 (1991).
13. Moorman AV, Richards S, Harrison CJ. Involvement of the MLL gene in T-lineage acute lymphoblastic leukemia. Blood 100(6), 2273-2273 (2002).
14. Hayette S, Tigaud I, Maguer-Satta V et al. Recurrent involvement of the MLL gene in adult T-lineage acute lymphoblastic leukemia. Blood 99(12), 4647-4649 (2002).
15. Cimino G, Sprovieri T, Rapanotti MC, Foà R, Mecucci C, Mandelli F. Molecular evaluation of the NUP98/RAP1GDS1 gene frequency in adults with T-acute lymphoblastic leukemia. Haematologica 86, 436-437 (2001).
16. Carlson KM, Vignon C, Bohlander S, Martinez-Climent JA, Le Beau MM, Rowley JD. Identification and molecular characterization of CALM/AF10 fusion products in T-cell acute lymphoblastic leukemia and acute myeloid leukemia. Leukemia 14(1), 100-104 (2000).
17. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, USA, November 1997. Histopathology 36, 69-86 (2000). Classification provides the aim to include genetic features in the classification of hematologic malignancies.
18. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91 (11), 3995-4019 (1998). Overview of the various genetic abnormalities detected in adult ALL.
19. Rowley JD. The critical role of chromosome translocations in human leukemias. Ann. Rev. Genet. 32, 495-519 (1998). Overviews the consequences of MLL and AML1 gene rearrangements in ALL and acute myeloid leukemia (AML).
20. Dombret H, Gabert J, Boiron J-M et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia - results of the prospective multicenter LALA-94 trial. Blood 100(7), 2357-2365 (2002). Clinical data including follow-up on 154 Philadelphia chromosome (P)-positive ALL patients of the LALA-94 trial including the results of stem cell transplantation procedures.
21. Annino L, Vegna ML, Camera A et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99(3), 863-871 (2002). Clinical data including follow-up on 778 adult ALL patients of the GIMEMA ALL 0288 randomized trial with a special focus on Ph-positive patients.
22. Bartram CR, de Klein A, Hagemeijer A et al. Translocation of c-ABL oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306, 277-280 (1983).
23. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcipt of ABL and BCR genes in chronic myeloid leukaemia. Nature 315, 550-554 (1985).
24. Chan LC, Karhi KK, Rayter SI et al. A novel ABL protein expressed in Philadelphia chromosome positive acute lymphoblastic leukemia. Nature 325, 635-637 (1987).
25. Fainstein E, Marcelle C, Rosner A et al. A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. Nature 330, 386-391 (1987).
26. Lugo TG, Pendergast AM, Muler AJ, Witte ON. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene product. Science 247, 1079-1083 (1990).
27. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of BCR is essential for the transforming function of BCR-ABL oncoproteins. Mol. Cell Biol. 13, 7587-7595 (1993).
28. Bedi A, Zehnbauer BA, Barberand JP, Sharkis SJ. Inhibiton of apoptosis by BCR/ABL in chronic myelogenous leukemia. Blood 83, 2038-2044 (1999).
29. Sirard C, Laneuville P, Dick J. Expression of BCR/ABL abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 83, 1575-1585 (1994).
30. Verfaille CM, McCarthy JB, McGlave PB. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukaemia. J. Clin. Invest. 90, 1232-1249 (1992).
31. Wetzler M, Dodge RY, Mrózek K et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia group B experience. Blood 93(11), 3983-3993 (1999). Clinical and cytogenetic data of the CALGB 8461 prospective trial on adult ALL based on 284 patients.
32. Charrin C, Magaud JP, Sebban D et al. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Groupe Français de Cytogénétique Hématologique. Blood 87(8), 3135-3142 (1996). Cytogenetic data on 443 French adult ALL patients.
33. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. Br. J. Haematol. 96, 601-610 (1997). Clinical and cytogenetic data of 350 adult ALL patients of the MRC UKALL XA trial.
34. Janssen JWG, Ludwig W-D, Borkhardt A et al. Pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission. Blood 84(11), 3835-3842 (1994).
35. Gu Y, Nakamura T, Alder H et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax to the AF-4 gene. Cell 71, 701-708 (1992).
36. Hess JL, Yu BD, Li B, Hanson R, Korsmayer JS. Defects in yolk sac hematopoiesis in MLL-null embryos. Blood 90, 1799-180 (1997).
37. Nakamura T, Alder H, Gu Y et al. Genes on chromosomes 4, 9 and 19 involved in 11q23 abnormalities in acute leukaemia share sequence homology and/or common motifs. Proc. Natl Acad. Sci. USA 90, 4631-4635 (1993).
38. Morrissey J, Tkachuk DC, Milatovich A, Francke U, Link M, Cleary ML. A serine/proline rich protein is fused to HRX in t(4;11) acute leukemias. Blood 81(5), 1124-1131 (1993).
39. Prasad R, Leshkowitz D, Gu Y et al. Leucine-zipper dimerization motif encoded by the AF17 gene fused to ALL-1 (MLL) in acute leukemia. Proc. Natl Acad. Sci. USA 91, 8107-8111 (1994).
40. Chaplin T, Ayton P, Bernard OA et al. A novel class of zinc finger/leucine zipper genes identified from the molecular cloning of the t(10;11) translocation in acute leukemia. Blood 85(6), 1435-1441 (1995).
41. Nilson I, Lochner K, Siegler G et al. Exon/ intron structure of the human ALL-1 (MLL) gene involved in translocations to chromosomal region 11q23 and acute leukemias. Br. J. Haematol. 93(4), 966-972 (1996).
42. Rubnitz JE, Behm FG, Downing JR. 11q23 rearrangements in acute leukemia. Leukemia 10, 74-75 (1996). Overview of the clinical and biological features of 11q23 leukemias and the mechanisms underlying MLL recombinations.
43. Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 87(4), 1211-1224 (1996). Overview of the involvement of E2A gene translocations in ALL.
44. Greenbaum S, Zhuang Y. Regulation of early lymphocyte development by E2A family protein. Semim. Immunol. 14(6), 405-414 (2002).
45. Kamps MP, Murre C, Sun XH, Baltimore D. A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell 160, 547-555 (1990).
46. Monica K, LeBrun DP, Dedera DA, Brown R, Cleary ML. Transformation properties of the E2A-Pbx1 chimeric oncoprotein: fusion with E2a is essential but the Pbx1 homeodomain is dispenable. Mol. Cell Biol. 14(12), 8304-8314 (1994).
47. Khalidi HS, O'Donnell MR, Slovak ML, Arber DA. Adult precursor-B acute lymphoblastic leukemia with translocations involving chromosome band 19p13 with poor prognosis. Cancer Genet. Cytogenet. 109(1), 58-65 (1999).
48. Gabert J, Vey N, Nabera CB et al. Improved outcome of adult patients with E2A PBX1/t(1;19) positive ALL after intensive therapy: results of the LAL-94 multicentric protocol. Blood 98, 840a (2001).
49. Inaba T, Roberts WM, Shapiro LH et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 257(5069), 531-534 (1992).
50. Inukai T, Inaba T, Yoshihara T, Look AT. Cell transformation mediated by homodimeric E2A-HLF transcription factor. Mol. Cell Biol. 17, 1417-1424 (1997).
51. Seidel MG, Look AT. E2A-HLF usurps control of evolutionarily conserved survival pathways. Oncogene 20(40), 5718-5725 (2002).
52. Look AT. E2A-HLF chimeric transcription factors in pro-B cell acute lymphoblastic leukemia. Curr. Top. Microbiol. Immunol. 220, 45-53 (1997).
53. McLean T, Ringold S, Neuberg D et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 88(11), 4654-4258 (1996).
54. Raynaud S, Mauvieux L, Cayuela JM et al. TEL/AML1 fusion gene is a rare event in adult acute lymphoblastic leukemia. Leukemia 10, 1529-1530 (1996).
55. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl Acad Sci. USA 93, 3444-3449 (1996).
56. Romana SP, Poirel H, Leconiat M et al. High frequency of the t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 86(11), 4263-4269 (1995).
57. Bernardin F, Yang Y, Cleaves R et al. TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia in mice. Cancer Res. 62(14), 3904-3908 (2002).
58. Hussey DJ, Nicola M, Moore S, Peters GB, Debrovic A. The (4;11)(q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphocytic leukemia. Blood 94(6), 2072-2079 (1999).
59. Kasper LH, Brindle PK, Schnabel CA, Pritchard CEJ, Cleary ML, van Deursen JMA. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol. Cell Biol. 19(1), 764-776 (1999).
60. Mecucci C, La Starza R, Negrini M et al. t(4;11) (q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukemia. Br. J. Haematol. 109, 788-793 (2000).
61. Dreyling MH, Martinez-Climent JA, Zheng M, Mao J, Rowley JD, Bohlander SK. The t(10;11)(p13;q14) in the U937 cell line results in the fusio of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. Proc. Natl Acad. Sci. US4 93, 4804-4809 (1996).
62. Bohlander SK, Muschinsky V, Schrader K et al. Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukaemia, acute lymphoblastic leukaemia and malignant lymphoma patients. Leukemia 14(1), 93-99 (2000).
63. Narita M, Shimizu K, Hayashi Y et al. Consistent detection of CALM-AF10 chimaeric transcripts in haematological malignancies with t(10;11)(p13;q14) and identification of novel transcripts. Br. J. Haematol. 105(4), 928-937 (1999).
64. Hiom K, Melek M, Gellert M. DNA transposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell 94, 463-470 (1998).
65. Macintyre EA, Delabesse E. Molecular approaches to the diagnosis and evaluation of lymphoid malignancies. Sem. Hematol. 36(4), 373-389 (1999). Overview of the molecular genetic events and their detection methods in lymphoma, ALL and multiple myeloma.
66. Taub R, Moulding C, Battey J et al. Activation and somatic mutation of the translocated c-MYC gene in Burkitt lymphoma cells. Cell 36, 339-348 (1984).
67. Goekbuget N, Hoelzer D. Recent approaches in acute lymphoblastic leukemia in adults. Rev. Clin. Exp. Hematol. 6(2), 114-141 (2002). Overview of the clinical features and therapeutic approaches in adult ALL.
68. Chen Q, Cheng J-T, Tsai L-H et al. The TAL gene undergoes chromosome translocation in T-cell leukemia and potentially encodes a helix-loop-helix protein. EMBO J. 9(2), 415-424 (1990).
69. Aplan PD, Lombardi DO, Reaman GH, Satzer HN, Hammond GD, Kirsch IR. Involvement of the putative hematopoietic transcription factor SCL in T-cell acute lymphoblastic leukemia. Blood 79(5), 1327-1333 (1992).
70. Begley CG, Green AR. The SCL gene: from case report to critical hematopoietic regulator. Blood 9(1), 2760-2770 (1999). Describes the various genetic events involving TAL-1 in hematopoietic neoplasms.
71. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc. Natl Acad. Sci. USA 88, 4367 (1991).
72. Wadman IA, Osada H, Grütz GG et al. The LIM-only protein LMO2 is a bridging molecule assembling an erythroid, DNA- binding complex which includes the TAL1, E47, GATA-1 and Lbd1/NLI proteins. EMBO J. 16(11), 3145-3157 (1997).
73. Larson RC, Lavenir I, Larson TA et al. Protein dimerization between LMO2 (BTN2) and TAL1 alters thymocyte development and potentiates T-cell tumorigenesis in transgenic mice. EMBO J. 15, 1021-1027 (1996).
74. Herblot S, Steff AM, Hugo P, Aplan PD, Hoang T. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T α-chain expression. Nature Immunol. 1(2), 97-98 (2000).
75. Chervinsky DS, Zhao XF, Lam DH, Ellsworth M, Gross KW, Aplan DP. Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice. Mol. Cell Biol. 19(7), 5025-5035 (1999).
76. Mellentin JD, Smith SD, Cleary ML. LYL-1, a novel gene altered by chromosomal translocation in T-cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 58, 77-83 (1989).
77. Aster JC, Pear WS. NOTCH signaling in leukemia. Curr. Opin. Hematol. 8(4), 237-244 (2001).
78. Artavanis-Tsakonas S, Rand MD, Lake RJ. NOTCH signalling: cell fate control and signal integration in development. Science 284, 770-776 (1999).
79. Hawley RG, Fong AZ, Reis MD, Zhang N, Lu M, Hawley TS. Transforming function of the HOX11/TCL3 homeobox gene. Cancer Res. 57, 337-345 (1997).
80. Pui C-H, Evans WE. Acute lymphoblastic leukemia. N. Engl. J. Med. 335, 605-615 (1998). Overview of adult ALL with a special look at biological characterization and risk assessment.
81. Ordentlich P, Lin A, Shen CP et al. NOTCH inhibition of E47 supports the existence of a novel signalling pathway. Mol. Cell Biol. 18(4), 2230-2239 (1998).
82. Hatta Y, Yamada Y, Tomonaga M, Miyoshi I, Said JW, Koeffler HP. Detailed deletion mapping of the long arm of chromosome 6 in adult T-cell leukemia. Blood 93(2), 613-616 (1999).
83. Mancini M, Vegna ML, Castoldi GL et al. Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia. Leukemia 16, 2055-2061 (2002).
84. Montpetit A, Boily G, Sinnett D. A detailed transcriptional map of the chromosome 12p12 tumour suppressor locus. Eur. J. Hum. Genet. 10(1), 62-71 (2002).
85. Brown SD, Twells RCJ, Hey PJ et al. Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family. Biochem. Biophys. Res. Com 248, 879-888 (1998).
86. Guo B, Godzik A, Reed JC. BCL-G, a novel pro-apoptotic member of the BCL-2 family. J. Biol. Chem. 276(4), 2780-2785 (2001).
87. Behrendt H, Charrin C, Gibbons B et al. Dicentric (9;12) in acute lymphoblastic leukemia and other hematological malignancies: report from a dic(9;12) study group. Leukemia 9, 102-106 (1995).
88. Clark R, Byatt SA, Bennett CF et al. Monosomy 20 as a pointer to dicentric (9;20) in acute lymphoblastic leukemia. Leukemia 14(2), 241-246 (2000).
89. Nobori T, Miura K, Wu D, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753-756 (1994).
90. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371, 257-261 (1994).
91. Malumbres M, Perez De Castro I, Hernandez MI, Jimenez M, Corral T, Pellicer A. Cellular response to oncogenic RAS involves induction of the CDK4 and CDK6 inhibitor p15(INK4b). Mol. Cell Biol. 20(8), 2915-2925 (2000).
92. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993-1000 (1995).
93. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92(6), 712-723 (1998).
94. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86(3), 841-854 (1995).
95. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12, 845-859 (1998). Literature overview of alterations of the INK4 cyclin-dependent kinase inhibitor in more than 4700 primary cases of leukemia and lymphomas in children and adults.
96. Kitagawa Y, Inou K, Sasaki S et al. Prevalent involvement of illegitimate V(D)J recombination in chromosome 9p21 deletions in lymphoid leukemia. J. Biol. Chem. 277(48), 46289-46297 (2002).
97. INK4b deletions in adult acute lymphoblastic leukemia. Clin. Cancer Res. 5, 1855-1861 (1999).
98. Stock W, Tsai T, Golden C et al. Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia. Blood 95(7), 2364-2371 (2000).
99. INK4Bgene alterations in adult patients with precursor B-cell acute lymphoblastic leukemia is a favourable prognostic factor. Br. J. Haematol. 117, 531-540 (2002).
100. Chim CS, Tam CYY, Liang R, Kwong YL. Methylation of p15 and p16 genes in adult acute leukemia. Cancer 91 (12), 2222-2229 (2001).
101. Wong IHN, Ng MHL, Hunag DP, Lee JCK. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 95 (6), 1942-1949 (2000).
102. Garcia-Manero G, Daniel J, Smith TL et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphoblastic leukemia. Clin. Cancer Res. 8, 2217-2224 (2002).
103. Hebert J, Cayuela JM, Berkeley J, Sibaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and M7S2 (p15INK4B) display frequent homozyous deletions in primary cells form T-cell but not from B-cell lineage acute lymphoblastic leukemia. Blood 84(12), 4038-4044 (1994).
104. Hayette S, Thomas X, Bertrand Y et al. Molecular analysis of cyclin-dependent inhibitors in human leukemias. Leukemia 11(10), 1696-1699 (1997).
105. Yamada Y, Hatta Y, Murata K et al. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J. Clin. Oncol. 15(5), 1778-1785 (1997).
106. KIP2 identifies a cell cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood (2003) (In Press). Identified patients with methylation of two or more cyclin-dependent inhibitors as a subgroup with a poor prognosis.
107. CIP1/WAF1/SDI1 gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 99(7), 2291-2296 (2002).
108. Corn PG, Kuerbitz SJ, van Noesel MM et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′CpG island methylation. Cancer Res. 59, 3352-3356 (1999).
109. Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R. Analysis of ras oncogene mutations in human lymphoid malignancies. Proc. Natl Acad. Sci. USA 85, 9268-9272 (1988).
110. Speletas M, Arvanitidis K, Tzoanopoulos D et al. Rapid mutational analysis of N-ras proto-oncogene in hematologic malignancies: a study of 77 greek patients. Haematologica 86, 918-927 (2001).
111. Nakao M, Janssen JW, Seriu T, Bartram CR. Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology Leukemia 14(2), 312-315 (2000).
112. Bayani J, Squire JA. Advances in the detection of chromosomal aberrations using spectral karyotyping. Clin. Genet. 59, 65-73 (2001). Summarizes the advantages of spectral karyotyping as a tool for subtle karyotypic diagnostics.
113. Nordgren A, Schoumans J, Soderhall S, Nordenskjold M, Blennow E. Interphase fluorescence in situ hybridization and spectral karyotyping reveals hidden genetic aberrations in children with acute lymphoblastic leukemia and a normal banded karyotype. Br. J. Haematol. 114(4), 786-793 (2001).
114. Kanerva J, Niini T, Vettenranta K et al. Loss of 12p detected by comparative genomic hybridization (CGH): association with TEL-AML1 fusion and favorable prognostic features in childhood acute lymphoblastic leukemia (ALL). A multi-institutional study. Med. Pediatr. Oncol. 37, 419-425 (2001).
115. Mathew S, Behm FG, Dalton J, Raimondi SC. Comparison of cytogenetics, Southern blotting and fluorescence in situ hybridisation as methods for detecting MLL gene rearrangements in children with acute leukemia and with 11q23 abnormalities. Leukemia 13, 1713-1720 (1999).
116. van Dongen JJM, Macintyre EA, Gabert JA et al. Standardized RT-PCR analysis of fusion gene transcripts from chromsome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 13, 1901-1928 (1999). Amis to provide the most relevant translocations in standardized RT-PCR diagnostics.
117. Brown L, Cheng JT, Chen Q et al. Site-specific recombination of the TAL-1 gene is a common occurrence in human T-cell leukemia. EMBO J. 9(10), 3343-3351 (1990).
118. Mecucci C, La Starza R, Negrini M et al. t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukemia. Br. J. Haematol. 109, 788-793 (2000).
119. Hunger SP, Fall MZ, Camitta BM et al. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemais with a t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 91(3), 1021-1028 (1998).
120. Strehl S, König M, Mann G, Haas OA. Multiplex reverse transcriptase-polymerase chain reaction screening in childhood acute myeloblastic leukemia. Blood 97(3), 805-808 (2001).
121. Raffini LJ, Slater DJ, Rappaport EF et al. Panhandle and reverse-panhandle PCR enable cloning of DER(11) and DER(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF4-4 and CDK6. Proc. Natl Acad. Sci. USA 99(7), 4568-4573 (2002).
122. Akasaka T, Muramatsu M, Ohno H et al. Application of long-distance polymerase chain reaction for detection of junctional sequences created by chromosomal translocation in mature B-cell neoplasms. Blood 88(3), 985-994 (1996).
123. Albitar M, Wu W, Feltz E et al. Simplified reverse dot blot analyses for detecting of ras oncogene mutations. Mol. Diagn. 2(3), 169-176 (1997).
124. Dewald GW, Wyatt WA, Juneau AL et al. High sensitivity flourescence in situ hybridization method to detect double BCR-ABL fusion and monitor reponse to therapy in chronic myeloid leukemia. Blood 91(9), 3357-3365 (1998).
125. Rieder H, Bonwetsch C, Janssen LAJ et al. High rate of chromosome abnormalities detected by fluorescnece in situ hybridization using BCR and ABL probes in adult acute lymphoblastic leukemia. Leukemia 12, 1473-1481 (1998).
126. Sinclair PB, Green AR, Grace C, Nacheva EP. Improved sensitivity of BCR-ABL detection: a triple-probe three color fluorescence in situ hybridization system. Blood 90(4), 1395-1402 (1997).
127. Boomer T, Varella-Garcia M, McGavran L, Meltesen L, Olsen AS, Hunger SP. Detection of E2A translocations in leukemias via fluorescence in situ hybridisation. Leukemia 15(1), 95-102 (2001).
128. Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 90(12), 4933-4937 (1997).
129. Siebert R, Matthiesen P, Hatder S et al. Application of interphase fluorescence in situ hybridization for the detection of the Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas. Blood 91, 984-990 (1998).
130. Ballerini P, Blaise N, Busson-Le Coniat M et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with a poor prognosis. Blood 100(3), 991-997 (2002).
131. Kahl C, Gesk S, Harder L et al. Detection of translocations involving the HOX11/TCL3-locus in 10q24 by interphase fluorscence in situ hybridization. Cancer Genet. Cytogenet. 129(1), 80-84 (2001).
132. Jackson A, Carrare P, Duke V et al. Deletion of 6q16-q21 in human lymphoid malignancies: a mapping and deletion analysis. Cancer Res. 60(11), 2775-2779 (2000).
133. van der Burg M, Smit B, Brinhof B et al. A single split-signal FISH probe set allows detection of TAL1 translocations as well as SIL-TAL1 fusion genes in a single test. Leukemia 16(4), 755-761 (2002).
134. Kim HJ, Cho HI, Kim EC et al. A study on 289 consecutive Korean patients with acute leukemias revealed fluorescence in situ habridization detects the MLL translocation without cytogenetic evidence both initially and during follow-up. Br. J. Haematol. 119, 930-939 (2002).
135. Wuchter C, Harbott J, Schoch C et al. Detection of acute leukemia cells with mixec lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1. Leukemia 14, 1232-1238 (2000).
136. Sang BC, Shi L, Dias P et al. Monoclonal antibodies specific to the acute lymphoblastic leukemia t(1;19)-associated E2A/PBX1 chimeric protein: characterization and diagnostic utility. Blood 89(8), 2909-2914 (1997).
137. Hoelzer D, Gökbuget N, Ottmann O et al. Acute lymphoblastic leukemia. Hematology 162-192 (2002). Composed of four parts focussing on clinical management of ALL, long-term sequelae of childhood ALL, hematopoietic cell transplantation for ALL and minimal residual disease in acute lymphoblastic leukemia.
138. Coustan-Smith E, Sancho J, Hancock ML et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 100(7), 2399-2402 (2002).
139. Cross NCP, Feng L, Chase A, Bungey J, Hughes TR, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82, 1929-1936 (1993).
140. Scheuring UJ, Pfeifer H, Wassmann B et al. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia with the ABL-tyrosine kinase inhibitor imatinib (STI571). Blood 101(1), 85-90 (2003).
141. Privitera E, Rivolta A, Ronchetti D, Mosna G, Giudici G, Biondi A. Reverse transcriptase-polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukemia. Br. J. Haematol. 92(3), 653-658 (1996).
142. Drunat S, Olivi M, Brunie G et al. Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukemia. Br. J. Haematol. 114, 281-289 (2001).
143. Willemse MJ, Seriu T, Hettinger K et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 99(12), 4386-4393 (2002).
144. Siraj AK, Ozbek U, Sazawal S et al. Preclinical validation of a monochromome real-time multiplex assay for translocations in childhood acute lymphoblastic leukemia. Clin. Cancer Res. 8, 3832-3040 (2002).
145. Guo JQ, Lin H, Kanterjian H et al. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 16, 2447-2453 (2002).
146. Verhagen OJHM, Willemse MJ, Breunis WB et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 14, 1426-1435 (2000).
147. Brüggemann M, Droese J, Bolz I et al. Improved assessment of minimal residual disease in B-cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia 4, 1419-1425 (2000).
148. Szcepaski T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJM. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 99, 2315-2323 (2002).
149. Cave H, van der Werff ten Bosch J, Suciu S et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N. Engl. J. Med. 339, 591-598 (1998).
150. Foroni L, Coyle LA, Papaioannou M et al. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukemia reveals differences in treatment response. Leukemia 11, 1732-1741 (1997).
151. Mortuza FY, Papaioannou M, Moreira IM et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J. Clin. Oncol. 20, 1094-1104 (2002).
152. Krampera M, Vitale A, Vincenzi C et al. Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukemia. Br. J. Haematol. 120, 74-79 (2003).
153. Cimino G, Elia L, Rapanotti MC et al. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood 95(1), 96-101 (2000).
154. Kantarjian HM, O'Brien S, Smith TL et al. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J. Clin. Oncol. 18(3), 547-561 (2000).
155. Forrest DL, Nevill TJ, Horsman DE et al. Bone marrow transplantation for adults with acute leukaemia and 11q23 chromosomal abnormalities. Br. J. Haematol. 103, 630-638 (1998).
156. Cornelissen JJ, Carston M, Kollman C et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 97(6), 1572-1577 (2001).
157. Sotomayer EM, Piantadosi S, Miller CB et al. Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy. Leuk. Res. 26(5), 461-471 (2002).
158. Abdallah A, Egerer G, Goldschmidt H et al. Continuous complete remission in adult patients with acute lymphocytic leukemia at a median observation of 12 years after autologous bone marrow transplantation. Br. J. Haematol. 112, 1012-1015 (2001).
159. Powles R, Sirohi B, Treleaven J et al. The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood 100(5), 1641-1647 (2002).
160. Gorin N-C. Autologous stem cell transplantation for adult acute leukemia. Curr. Opin. Oncol. 14, 152-159 (2002).
161. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukaemia with the Philadelphia chromosome. N. Engl. J. Med 344 (14), 1038-1042 (2001). Initial data on the clinical application of STI571 in ALL patients.
162. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1084-1086 (2001).
163. + acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99(5), 1860-1862 (2002).
164. Gorre ME, Mohammad M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
165. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an ABL tyrosine kinase inhibitor, in conjunction with other anitleukemic agents against BCR-ABL-positive cells. Blood 96(9), 3195-3199 (2000).
166. Vigneri P, Wang JYJ. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entraping of BCR-ABL tyrosine kinase. Nat. Med 7(2), 228-234 (2001).
167. Wisniewski D, Lambek CL, Liu C et al. Characterization of potent inhibitors of the BCR-ABL and the c-KIT receptor tyrosine kinases. Cancer Res. 62, 4244-4255 (2002).
168. Golas JM, Arndt K, Erienne C et al. SKI-606, a 4-Anilino-3-quinolinecarbonitrile dual inhibitor of SRC and ABL kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63, 375-381 (2003).
169. Kuwabara T, Tanabe T, Warashina M et al. Allosterically controllable maxizyme-mediated suppression of progression of leukemia in mice. Biomacromolecules 2(4), 1220-1228 (2001).
170. Wilda M, Fuchs U, Wossmann W, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 21(37), 5716-5724 (2002).
171. Saito A, Yamashita T, Mariko Y et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl Acad Sci. USA 96, 4592-4597 (1999).
172. Cheng JC, Matsen CB, Gonzales FA et al. Inhibition of DNA methylation and reactivation of silenced genes by Zebularine. J. Natl Cancer Inst. 95(5), 399-409 (2003).
173. Armstrong SA, Staunton JE, Silverman LB et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30, 41-47 (2002). Unique expression profile for the subset of MLL translocation positive leukemias.
174. Ferrando AA, Neuberg DS, Staunton J et al. Gene expression signatures define novel oncogenic pathways in T-cell acute lymphoblastic leukemia. Cancer Cell 1(1), 75-87 (2002). Demonstrates the expression profiling data in T-cell leukemias illustrating specific, prognostic relevant changes of gene expression signatures.